- Tiziana Life Sciences' drug milciclib, a small molecular pan-inhibitor of cyclin dependent kinases (CDKs), has met its primary endpoints in the two phase II clinical trials in patients with thymic carcinoma and thymoma.

The treatment regimen with milciclib was safe and well-tolerated in these patients with continuing exposure of up to five years.

Two separate phase II multi-centred clinical trials in patients with thymic carcinoma and thymoma, respectively, were conducted in the US, France and Italy. Thymic carcinoma is a metastatic malignancy which is generally accepted as being more difficult to treat than thymoma.

Both clinical studies demonstrated that treatment with milciclib was efficacious and met progression free survival as the primary endpoint and overall survival as a secondary endpoint.

Gabriele Cerrone, chairman of Tiziana Life Sciences, said: "Thymic carcinoma and thymoma are unmet medical needs with no approved therapies. It is very promising that milciclib has again been shown to be a safe and efficacious drug. Milciclib could potentially be the first single agent for long-term treatment of these rare cancers."

At 9:13am: [LON:TILS] Tiziana Life Sciences Plc share price was +10p at 160p

Story provided by